

| | | |
|--|--|--|
| TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED / ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 | | ATTORNEY'S DOCKET NUMBER P67671US0 |
| | | US APPLICATION NO. (If known, see 37 CFR 1.51) 10/069128 |
| INTERNATIONAL APPLICATION NO. PGT/EP00/08545 | INTERNATIONAL FILING DATE 1 September 2000 | PRIORITY DATE CLAIMED 3 September 1999 |
| TITLE OF INVENTION USE OF NATRIURETIC PEPTIDES AS ANTIBIOTICALLY ACTIVE SUBSTANCES FOR THE TREATMENT OF BACTERIAL INFECTIONS | | |
| APPLICANT(S) FOR DO/EO/US Wolf-Georg FORSSMANN, Alexander KRAUSE and Erik MARONDE | | |

Applicant herein submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for Internatl. Preliminary Examination was made by the 19th month from earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the Internatl. Preliminary Examination report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
 ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
Sequence Listing - 2 Pages

| US APPLICATION NO. (If known, see 37 CFR 1.53) 107069128 | | INTERNATIONAL APPLICATION NO PCT/EP00/08545 | | ATTORNEY'S DOCKET NUMBER P67671US0 | | | | | |
|--|---------------------|---|-------------|---|----|--------------|--------------|-----------|--|
| 17. <input checked="" type="checkbox"/> The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)): Internatl. prelim. examination fee paid to USPTO (37 CFR 1.492 (a) (1)) .. \$710.00 No international preliminary examination fee paid to USPTO (37 CFR 1.492 (a) (2)) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) .. \$740.00 Neither international preliminary examination fee (37 CFR 1.492 (a) (3)) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO) \$1040.00 International preliminary examination fee paid to USPTO (37 CFR 1.492 (a) (4)) and all claims satisfied provisions of PCT Article 33(2)-(4) \$100.00 Search Report prepared by the EPO or JPO (37 CFR 1.492 (a) (5)) \$890.00 <div style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div> | | | | <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 50%;">CALCULATIONS</th> <th style="width: 50%;">PTO USE ONLY</th> </tr> <tr> <td style="height: 100px; vertical-align: bottom;">\$ 890.00</td> <td></td> </tr> </table> | | CALCULATIONS | PTO USE ONLY | \$ 890.00 | |
| CALCULATIONS | PTO USE ONLY | | | | | | | | |
| \$ 890.00 | | | | | | | | | |
| Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)). | | | | <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">\$</td> <td style="width: 50%;"></td> </tr> </table> | | \$ | | | |
| \$ | | | | | | | | | |
| Claims | Number Filed | Number Extra | Rate | | | | | | |
| Total Claims | 7 - 20 = | -0- | x \$18.00 | \$ | | | | | |
| Independent Claims | 1 - 3 = | -0- | x \$84.00 | \$ | | | | | |
| Multiple Dependent Claim(s) (if applicable) | | | + \$280.00 | \$ | | | | | |
| TOTAL OF ABOVE CALCULATIONS = | | | | \$ 890.00 | | | | | |
| Reduction by 1/2 for filing by small entity , if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28). | | | | <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">\$</td> <td style="width: 50%;"></td> </tr> </table> | | \$ | | | |
| \$ | | | | | | | | | |
| SUBTOTAL = | | | | \$ 890.00 | | | | | |
| Processing fee of \$130 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)) | | | | <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">\$</td> <td style="width: 50%;"></td> </tr> </table> | | \$ | | | |
| \$ | | | | | | | | | |
| TOTAL NATIONAL FEE = | | | | \$ 890.00 | | | | | |
| Fee of \$40.00 for recording the enclosed assignment (37 CFR 1.21(h)). Assignment must be accompanied by appropriate cover sheet (37 CFR 3.28, 3.31). | | | | <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">\$ 40.00</td> <td style="width: 50%;"></td> </tr> </table> | | \$ 40.00 | | | |
| \$ 40.00 | | | | | | | | | |
| TOTAL FEES ENCLOSED = | | | | \$ 930.00 | | | | | |
| | | | | Amt. to be refunded: | \$ | | | | |
| | | | | Amt. charged: | \$ | | | | |

a. ☒ A check in the amount of \$ 930.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. 06-1358 in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge my account any additional fees set forth in §1.492 during the pendency of this application, or credit any overpayment to Deposit Account No. 06-1358. A duplicate copy of this sheet is enclosed.

SEND ALL CORRESPONDENCE TO:

JACOBSON HOLMAN PLLC
 400 7th Street, N.W., Suite 600
 Washington, DC 20004
 202-638-6666
CUSTOMER NUMBER: 00136

By
 William E. Player
 Reg. No. 31,409

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Wolf-Georg FORSSMANN et al
Serial No.: New
Filing Date: March 4, 2002
For: USE OF NATRIURETIC PEPTIDES AS ANTIBIOTICALLY
ACTIVE SUBSTANCES FOR THE TREATMENT OF BACTERIAL
INFECTIONS

PRELIMINARY AMENDMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Prior to initial examination, please amend the above-
identified application as follows:

IN THE SPECIFICATION

Please insert the following sentence on line 1, immediately
following the title:

--This is a 371 of PCT/EP00/08545, filed September 1, 2000,
the disclosure of which is incorporated herein by reference.--

IN THE CLAIMS

Please cancel claims 1-7 without prejudice or disclaimer.

Please add new claims 8-14 as found on the following page.

CLAIMS:

8. Use of natriubiotics for the preparation of an antibiologically active agent for the treatment of a pathogenically altered bacterial flora in the gastrointestinal tract, respiratory and urogenital systems, the skin, and for use in food technology as an auxiliary agent in fermenting processes and as a preservative.
9. The use according to claim 8, wherein said natriubiotics are formulated in amounts of from 1 μ g to 1 mg per unit for infusions, ointments, tablets, sprays or sustained release capsules.
10. The use according to claim 8 for the treatment of alterations of the intestinal flora.
11. The use according to claim 8 for the treatment of alterations of microbially induced skin diseases.
12. The use according to claim 8 for the treatment of aberrations of the human vaginal flora.
13. The use according to claim 8 as a preservative for foods or other perishable goods.
14. The use according to claim 8 as an auxiliary agent in industrial fermenting processes, e.g., in beer production, in yogurt production and in sauerkraut production.

REMARKS


The foregoing Preliminary Amendment is requested in order to delete the multiple dependent claims and avoid paying the multiple dependent claims fee.

Early action on the merits is respectfully requested.

Respectfully submitted,

JACOBSON HOLMAN PLLC

By


William E. Player
Reg. No. 31,409

400 Seventh Street, N.W.
Washington, D.C. 20004-2201
(202) 638-6666

Atty. Docket: P67671US0
Date: March 4, 2002
WEP:jrc

2/PR15

10/069128

JC19 Rec'd PCT/PTO 04 MAR 2002

SMB

Use of Natriuretic Peptides as Antibiotically Active Substances
for the Treatment of Bacterial Infections

The present invention relates to the use of natriuretic peptides (ANP, BNP, CNP and urodilatin) as antibiotically active peptide preparations. The peptides are obtained by chemical peptide synthesis or biotechnological production, and confectioning as a galenically prepared substance for medical and veterinary use as a medicament.

The peptides to which this invention relates are members of the family of natriuretic peptides. The primary structures of atrial natriuretic peptide (ANP) of rats (Flynn et al., 1983), pigs (Forssmann et al., 1983, 1984) and humans (Kangawa and Matsuo, 1984) have been described. The form of ANP which occurs in the kidneys, urodilatin, was first isolated in 1988 by Forssmann et al. (Schulz-Knappe et al., 1988). The homologue of atrial natriuretic peptide (ANP), the brain-type natriuretic peptide (BNP), was first isolated in 1988 by Sudoh et al. To date, an antibiotic activity of natriuretic peptides has not been suggested. To prove antimicrobial activity, a test is preferably performed which is suitable for basic peptides. A useful test for recognizing antibiotic activity is the growth inhibition test of Lehrer et al. (Lehrer et al., J. Immun. Methods, Vol. 137, p. 167, 1991).

It has been the object of the invention to provide antibiotically active agents. This object is achieved by the use of natriuretic peptides (natriubiotics, such as ANP, BNP, CNP and urodilatin) according to claim 1. The dependent claims relate to preferred embodiments of the use according to the invention.

According to the invention, the natriubiotics are used for the preparation of an antibiotically active agent for the treatment of a pathogenically altered bacterial flora in the gastro-intestinal tract, respiratory and urogenital systems, the skin,

When used as medicaments, the natriubiotics are preferably formulated in amounts of from 1 µg to 1 mg per unit into infusions, ointments, tablets, sprays or sustained release capsules.

The use of natriubiotics according to the invention also comprises the treatment of alterations of the intestinal flora, the treatment of microbially induced skin diseases, the treatment of aberrations of the human vaginal flora. The use of natriubiotics in food technology according to the invention also comprises the use as a preservative for foods or other perishable goods, as an auxiliary agent in industrial fermenting processes, e.g., in beer production, in yogurt production and in sauerkraut production.

Surprisingly, human ANP 99-126 and urodilatin have a growth-inhibiting effect on Gram-positive bacteria, such as *B. subtilis*, *M. luteus* and *S. carnosus*, and on Gram-negative bacteria, such as *E. coli*, *N. cinerea* and *P. fluorescens*, and the yeast *S. cerevisiae*. Also, human BNP-312 has the same growth-inhibiting effect on Gram-positive bacteria, such as *B. subtilis*, *M. luteus* and *S. carnosus*, and on Gram-negative bacteria, such as *E. coli*, *N. cinerea* and *P. fluorescens*, and the yeast *S. cerevisiae*. The growth-modulating property of these specific natriuretic peptides on certain germs has been unequivocally proven for the first time.

By chemical and biotechnological synthesis, the natriuretic peptides can be prepared in a highly pure and biologically active form and employed as a medicament.

The substances which can be used according to the invention, consisting of synthetic and recombinant products, can change the bacterial flora of the intestine, the skin and other bacterially colonized body zones and lead to an improvement of the germ flora in bacterial colonization by misplaced species. Therefore, the isolated pure substances can be used for controlling diarrheas, especially infant diarrheas, i.e., infections of the gastro-intestinal tract, but also of the respiratory system, the urogenital system and in skin infections. The preparations can be used

as additives for foods or as therapeutic agents and serve as auxiliary agents in the production of foods, especially in foods which are prepared by fermentation and other bacterial processes. These preparations are natural preservatives.

In the following, the invention is illustrated by means of Examples and the following Figures to which reference is made in the Examples:

Figure 1 shows a growth inhibition test of ANP

Radial diffusion growth inhibition test with *Streptococcus carnosus* and *N. cinerea* according to Lehrer et al. (Lehrer et al., J. Immun. Methods, Vol. 137, p. 167, 1991). The growth inhibition test is particularly suitable for the detection of antibiotic peptides since a special agarose which does not contain any fixed charged sites was used as the support material instead of the otherwise usual agar-agar. After application of 1 µg of ANP (both germs), inhibition halos can be observed.

Figure 2 shows a growth inhibition test of urodilatin

Radial diffusion growth inhibition test with *Streptococcus carnosus* and *N. cinerea* according to Lehrer et al. (Lehrer et al., J. Immun. Methods, Vol. 137, p. 167, 1991). The growth inhibition test is particularly suitable for the detection of antibiotic peptides since a special agarose which does not contain any fixed charged sites was used as the support material instead of the otherwise usual agar-agar. After application of 1 µg of urodilatin (both germs), inhibition halos can be observed.

Figure 3 shows a growth inhibition test of BNP-32

Radial diffusion growth inhibition test with *Streptococcus carnosus* and *N. cinerea* according to Lehrer et al. (Lehrer et al., J. Immun. Methods, Vol. 137, p. 167, 1991). The growth inhibition test is particularly suitable for the detection of antibiotic peptides since a special agarose which does not contain any fixed charged sites was used as the support material instead of the otherwise usual

agar-agar. After application of 0.1 µg of BNP (both germs), inhibition halos can be observed.

Figure 4 shows a growth inhibition test of CNP

Radial diffusion growth inhibition test with *Streptococcus carnosus* and *N. cinerea* according to Lehrer et al. (Lehrer et al., J. Immun. Methods, Vol. 137, p. 167, 1991). The growth inhibition test is particularly suitable for the detection of antibiotic peptides since a special agarose which does not contain any fixed charged sites was used as the support material instead of the otherwise usual agar-agar. After application of 7 µg (*S. carnosus*) and 11 µg (*N. cinerea*) of CNP, inhibition halos can be observed.

Example 1:

Chemical synthesis of the antibiotically active peptides ANP, BNP, urodilatin and CNP

Strategy of the synthesis of human natriuretic peptides:

For the synthesis of the peptides with the following sequences:

Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-
Ala-Gln-Ser-Gly-Leu-Gly-

Cys-Asn-Ser-Phe-Arg-Tyr (ANP/CDD)

Ser-Phe-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-

Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His (BNP)

Gly-Leu-Ser-Lys-Gly-Cys-Phe-Gly-Leu-Lys-Leu-Asp-Arg-Ile-Gly-Ser-Met-
Ser-Gly-Leu-Gly-Cys (CNP)

Thr-Ala-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-
Arg-Ile-Gly-Ala-Gln-

Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (urodilatin),1

the continuous flow method (Atherton and Sheppard, in "Solid Phase Peptide Synthesis, IRL Press, Oxford 1989) has been used. The peptide sequence mentioned is synthesized by means of an automated peptide synthesis apparatus (Minigen 9050) using Fmoc amino acids. The Fmoc amino acids had L-configuration and were employed in a fourfold excess.

The following amino acid derivatives were used for the synthesis:

Fmoc-Lys (Boc), Fmoc-Arg (Pmc), Fmoc-His (Trt), Fmoc-Glu (OtBu), Fmoc-Ser(tBu), Fmoc-Gln(Trt), Fmoc-Leu, Fmoc-Phe, Fmoc-Ile, Fmoc-Val.

Cys, Gly, Met and Asp are lacking.

The synthesis is performed with a C-terminal amino acid (0.091 mmol of alanine/g of resin) bound to Fmoc-L-Ala-PEG-PS support (Millipore). All coupling processes of amino acid derivatives were performed in the presence of O-(1H-benzotriazole-1-yl)-N,N'-N'-tetramethyluronium tetrafluoroborate (TBTU), 1-hydroxybenzotriazole and diisopropylethylamine. The following synthesis cycles were used:

- Fmoc deprotection with 20% piperidine in DMF for 10 min;
- washing with DMF for 12 min;
- acylation for 30 min;
- washing with DMF for 8 min.

The synthesis is monitored by continuous UV detection. The synthesis is concluded with the cleavage of the N-terminal Fmoc residue. The resin-bound peptide is washed three times with 50 ml each of isopropanol, glacial acetic acid, isopropanol and diethyl ether, and dried.

The peptides are cleaved from the carrier resin by adding a mixture of TFA-ethanedithiol-water (94:3:3; v/v/v) and precipitated with ether.

The purification of the peptide is effected by reversed-phase HPLC using a C18 column (Vydac, 10 µm 300 Å, 20 x 250 mm, detection at 230 nm). The following mobile solvents were used: eluent A: 0.06% trifluoroacetic acid (TFA); eluent B: 0.06% TFA in acetonitrile/water (4:1). The flow rate is 10 ml/min, and the gradient is as follows: from 20% B to 80% B within 70 min. The pure fractions are pooled and lyophilized.

The purity and identity of the peptides is determined by mass spectrometry (quadrupole electrospray mass spectrometry, Sciex API 111, Perkin Elmer) and sequencing in a gas-phase sequencer (model 470, Applied Biosystems, Weiterstadt) and checked by capillary zone electrophoresis. The biological activity is verified by the growth inhibition test.

Example 2:

Recombinant preparation

The recombinant preparation is effected by usual methods, resulting in a similarly pure peptide for galenic use.

CLAIMS:


1. Use of natriubiotics for the preparation of an antibiotically active agent for the treatment of a pathogenically altered bacterial flora in the gastro-intestinal tract, respiratory and urogenital systems, the skin, and for use in food technology as an auxiliary agent in fermenting processes and as a preservative.
2. The use according to claim 1, wherein said natriubiotics are formulated in amounts of from 1 µg to 1 mg per unit for infusions, ointments, tablets, sprays or sustained release capsules.
3. The use according to claims 1 and/or 2 for the treatment of alterations of the intestinal flora.
4. The use according to claims 1 and/or 2 for the treatment of alterations of microbially induced skin diseases.
5. The use according to claims 1 and/or 2 for the treatment of aberrations of the human vaginal flora.
6. The use according to claims 1 and/or 2 as a preservative for foods or other perishable goods.
7. The use according to claims 1 and/or 2 as an auxiliary agent in industrial fermenting processes, e.g., in beer production, in yogurt production and in sauerkraut production.

Abstract


The present invention relates to antibiotically active natriuretic peptides for use as antibiotically active preparations prepared using biotechnological and recombinant methods and chemical synthesis. The antibiotically active peptides are referred to as natriubiotics. After chemical peptide synthesis, these natriubiotics can be used as human or veterinary medicaments in a suitable galenic formulation or as food additives.

- 1/2 -



ANP
S.carnosus + N.cinerea



Urodilatin
S.carnosus + N.cinerea



- 2/2 -

BNP
S.carnosus + *N.cinerea***CNP**
S.carnosus + *N.cinerea*

AND POWER OF ATTORNEY U.S.A.

ATTORNEYS' DOCKET NO.

ALL PATENTS, INCLUDING DESIGN
FOR APPLICATION BASED ON PCT, PARIS CONVENTION,
NON PRIORITY, OR PROVISIONAL APPLICATIONS

As a below named inventor, I declare that my residence, post office address and citizenship are stated below next to my name. The information given herein is true, that I believe that I am the original, first and sole inventor (if only one name is listed at 201 below), or an original, first and joint inventor (if plural inventors are named below at 201-203, or on additional sheets attached hereto) of the subject matter which is claimed and for which patent is sought on the invention entitled:

USE OF NATRIURETIC PEPTIDES AS ANTIBIOTICALLY ACTIVE SUBSTANCES FOR THE TREATMENT OF BACTERIAL INFECTIONS

which is described and claimed in: ☒ PCT International Application No. PCT/EP00/08545 filed September 1, 2000
☐ the attached specification ☐ the specification in application Serial No. _____ filed _____
(if applicable) and amended on _____

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.86.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

| Prior Foreign Application(s) | (Number) | (Country) | (Day/Month/Year Filed) | Priority Claimed |
|------------------------------|-----------|------------------------|---|------------------|
| 199 42 230.3 | Germany | September 3, 1999 | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No | |
| (Number) | (Country) | (Day/Month/Year Filed) | <input type="checkbox"/> Yes <input type="checkbox"/> No | |
| (Number) | (Country) | (Day/Month/Year Filed) | <input type="checkbox"/> Yes <input type="checkbox"/> No | |

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

| Application No. | Filing Date | Application No. | Filing Date |
|-----------------|-------------|-----------------|-------------|
| | | | |

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

| (Application Serial No.) | (Filing Date) | (Status: patented, pending, abandoned) |
|--------------------------|---------------|--|
| | | |

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys (Registration No.) to prosecute this application, receive and act on instructions from my agent, and transact all business in the Patent and Trademark Office connected therewith. HARVEY B. JACOBSON, JR. (20,851); JOHN CLARKE HOLMAN (22,769); MARVIN R. STERN (20,840); ALLEN S. MELSER (27,215); MICHAEL R. SLOBASKY (26,421); JONATHAN L. SCHERER (29,851); IRWIN M. AISENBERG (19,007); WILLIAM E. PLAYER (31,409); YOON S. HAM (45,307) and NATHANIEL A. HUMPHRIES (22,772)

SEND CORRESPONDENCE TO: CUSTOMER NO. 00136

or

JACOBSON HOLMAN
PROFESSIONAL LIMITED LIABILITY COMPANY
400 SEVENTH STREET, N.W.
WASHINGTON, D.C. 20004

DIRECT TELEPHONE CALLS TO:

(please use Attorney's Docket No.) (202) 638-8686

JACOBSON HOLMAN
PROFESSIONAL LIMITED LIABILITY COMPANY

*Inventor(s) name must include at least one unabbreviated first or middle name.

| | FULL NAME OF INVENTOR | FAMILY NAME | GIVEN NAME | MIDDLE NAME |
|-----|-----------------------|--------------------------|------------------------|-------------|
| 201 | Forssmann | Wolff-Georg | | |
| | CITY | STATE OR FOREIGN COUNTRY | COUNTRY OF CITIZENSHIP | |
| | Hannover | Germany | Germany | |
| | POST OFFICE ADDRESS | CITY | STATE OR COUNTRY | ZIP CODE |
| | Blücherstr. 5 | Hannover | Germany | 30175 |
| 202 | Krause | Alexander | | |
| | CITY | STATE OR FOREIGN COUNTRY | COUNTRY OF CITIZENSHIP | |
| | Rinteln | Germany | Germany | |
| | POST OFFICE ADDRESS | CITY | STATE OR COUNTRY | ZIP CODE |
| | Im Obernfeld 21 | Rinteln | Germany | 31737 |
| 203 | Maronde | Erik | | |
| | CITY | STATE OR FOREIGN COUNTRY | COUNTRY OF CITIZENSHIP | |
| | Hannover | Germany | Germany | |
| | POST OFFICE ADDRESS | CITY | STATE OR COUNTRY | ZIP CODE |
| | De-Vries-Hof 3 | Hannover | Germany | 30627 |

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under section 1001 of Title 18 of the United States Code; and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

| SIGNATURE OF INVENTOR 201 | SIGNATURE OF INVENTOR 202 | SIGNATURE OF INVENTOR 203 |
|------------------------------|---------------------------|---------------------------|
| <i>Wolff-Georg Forssmann</i> | <i>Alexander Krause</i> | <i>Erik Maronde</i> |
| DATE <u>31.01.2002</u> | DATE <u>31.01.2002</u> | DATE <u>31.01.2002</u> |

☐ Additional inventors are named on separately numbered sheets attached hereto.

© JH 2001 (COPYING WITHOUT DELETIONS PERMITTED)

SEQUENCE LISTING

<110> Forssmann, Wolf-Georg
Krause, Alexander
Maronde, Erik

<120> Use of Natriuretic Peptides as Antibiotically Active
Substances for the Treatment of Bacterial Infections

<130> 020265us

<140>

<141>

<150> DE19942230.3

<151> 1999-09-03

<160> 4

<170> PatentIn Ver. 2.1

<210> 1

<211> 28

<212> PRT

<213> Homo sapiens

<400> 1

Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly
1 5 10 15

Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
20 25

<210> 2

<211> 32

<212> PRT

<213> Homo sapiens

<400> 2

Ser Phe Lys Met Val Gln Gly Ser Gly Cys Phe Gly Arg Lys Met Asp
1 5 10 15

Arg Ile Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His
20 25 30

<210> 3
 <211> 22
 <212> PRT
 <213> Homo sapiens

<400> 3
 Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser
 1 5 10 15
 Met Ser Gly Leu Gly Cys
 20

<210> 4
 <211> 32
 <212> PRT
 <213> Homo sapiens

<400> 4
 Thr Ala Pro Arg Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met
 1 5 10 15
 Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
 20 25 30